SMS Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

6.66×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.81×	1.81×	1.71×	1.61×	1.61×
0.81×	0.81×	0.83×	0.90×	0.73×
45.9	45.9	41.4	36.0	7.4
285	285	230	202	156

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersINDSWFTLAB SOLARA DCAL UNICHEMLAB GUFICBIO RPGLIFE HIKAL GUJTHEMMcap ₹4,453 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	6.66
Current Ratio	1.61	1.61	1.71	1.81	1.81
Quick Ratio	0.73	0.90	0.83	0.81	0.81
Cash, Equiv & ST Investments	7.4	36.0	41.4	45.9	45.9
Working Capital	155.7	202.2	230.1	285.0	285.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.